Take­da is ready to auc­tion off a PhI­II fa­vorite at Shire to clear the last hur­dles to a $62B buy­out

For sale: A promis­ing in­flam­ma­to­ry bow­el dis­ease drug now in Phase III stud­ies for ul­cer­a­tive col­i­tis and Crohn’s dis­ease, once de­scribed by the ex­ec­u­tive team at Shire as one of the most pre­cious “gems’ in its late-stage pipeline. In­quire at Take­da.

Look­ing for a late-stage as­set that might just be ready in the not too dis­tant fu­ture to be teed up for one of the hottest mar­ket­places in the world?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER